Immunology Product Guide » Gardasil

The FDA committee recommends use of GARDASIL on boys and men

Jim Marino — Wed, 23 Sep 2009 04:22:29 +0000

The FDA Vaccines and Related Biological Products Advisory Committee agreed on the efficacy, immunogenicity and safety data of Merck & Co Inc’s . The clinical trials support the use of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for boys and men aged 9 to 26 years for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

Gardasil gets through safety check

Jim Marino — Wed, 29 Oct 2008 10:30:10 +0000

After two years of its approval, the Advisory Committee on Immunization Practices has detected no major problems with the safety of the HPV vaccine, Gardasil. The vaccine is used to protect against infection caused by the sexually transmitted virus, the HPV, that leads to genital warts and cervical cancer. The Center for Disease Control and Prevention has recommended the vaccination of girls at the age of 11 (much before they turn sexually active). No serious side effects have been found.

FDA approves Gardasil against vaginal and vulvar cancers

Jim Marino — Tue, 16 Sep 2008 07:14:02 +0000

Merck’s cervical vaccine Gardasil has been approved by the U.S. Food and Drug Administration for protection against vaginal and vulvar cancers caused by Human Papilloma Virus (HPV) types 16 and 18 for females aged from 9 to 26. The vaccine is already used for prevention of cervical cancer, approval for which was given by FDA in 2006. Gardasil does not work if you are already infected when you become vaccinated. Women should undergo regular screening to get precancerous lesions detected and receive treatment before cancer.